

(43) International Publication Date
18 September 2014 (18.09.2014)

(51) International Patent Classification:

A61K 47/02 (2006.01) A61K 9/14 (2006.01)
A61K 45/06 (2006.01) A61K 31/40 (2006.01)
A61K 9/00 (2006.01) A61K 31/4704 (2006.01)
A61K 47/24 (2006.01) A61K 31/58 (2006.01)

(21) International Application Number:

PCT/IB2014/059739

(22) International Filing Date:

13 March 2014 (13.03.2014)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/784,842 14 March 2013 (14.03.2013) US

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **HARTMAN, Michael** [US/US]; c/o Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, California 94070 (US). **TARARA, Thomas** [US/US]; c/o Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, California 94070 (US). **TEUNG, Patrick** [US/US]; c/o Novartis Pharmaceuticals Corporation, 150 industrial Road, San

Carlos, California 94070 (US). **WEERS, Jeffrey** [US/US]; c/o Novartis Pharmaceuticals Corporation, 150 Industrial Road, San Carlos, California 94070 (US).

(74) Agent: **MCLEAN, Craig**; Novartis Pharmaceuticals UK Limited, Wimbleshurst Road, Horsham Sussex RH12 5AB (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: RESPIRABLE AGGLOMERATES OF POROUS CARRIER PARTICLES AND MICRONIZED DRUG




Fig 1

(57) Abstract: A pharmaceutical composition for pulmonary delivery that is a dry powder that contains a porous carrier particles and active agent particles. The porous carrier particles and the active agent particles form an ordered mixture of respirable agglomerates that are useful to treat diseases of the lung. The active agent particles can comprise one, two, three or more active ingredients. A spray-drying process for preparing the respirable agglomerates is also described.



Published:

— *with international search report (Art. 21(3))*